The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS.
 
Prudence Francis
Honoraria - Amplity Health; Lilly
 
Gini Fleming
Research Funding - Abbvie (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Celldex (Inst); Compugen (Inst); Compugen (Inst); Corcept Therapeutics (Inst); Duality Biologics (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); K-Group Beta (Inst); Merck (Inst); Molecular Templates (Inst); P{fizer (Inst); Roche (Inst); Sanofi (Inst); Sermonix Pharmaceuticals (Inst)
 
Olivia Pagani
Consulting or Advisory Role - Debiopharm Group
 
Barbara Walley
Stock and Other Ownership Interests - Pfizer (I)
 
Sherene Loi
Honoraria - Adanate; Amaroq Therapeutics; Astra Zeneca / Daiichi Sankyo; Bicycle Therapeutics; BioNTech SE; Domain Therapeutics; Exact Sciences; Gilead Sciences; Menari Asia Pacific; Mersana; MSD Oncology; Novartis; Roche/Genentech; SAGA Diagnostics
Consulting or Advisory Role - AstraZeneca (Inst); BMS (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - BMS
Other Relationship - Roche Medical writing support
 
Marco Colleoni
No Relationships to Disclose
 
Meredith Regan
Honoraria - Bristol-Myers Squibb; Merck
Consulting or Advisory Role - Bristol-Myers Squibb; Tersera; Tolmar
Research Funding - Bayer (Inst); bioTheranostics (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
on behalf of SOFT and TEXT Investigators, IBCSG, BIG and North American BC Groups
No Relationships to Disclose